Date: 2015-03-26
Type of information: Nomination
Compound:
Company: Erytech Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 26, 2015, Erytech Pharma announced it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June. Luc Dochez, has served as Chief Business Officer and Senior Vice-President of Business Development of Prosensa since November 2008 until its recent acquisition by Biomarin. At Prosensa, Luc has been instrumental in signing a >$500M licensing deal with GSK, he has been actively involved in the successful listing on NASDAQ and he has managed the process leading to the acquisition of the company by BioMarin for $860M. Mr. Dochez has over 15 years of experience in the biotechnology industry. Before joining Prosensa, he was a consultant within Arthur D. Little’s biotechnology practice, Director of Business Development at Methexis Genomics, Vice President of Business Development at TiGenix N.V. and President of TiGenix Inc. Mr. Dochez holds a Pharm.D. degree from the University of Leuven , a postgraduate degree in business economics from the same university and an M.B.A. degree from Vlerick Management School. The appointment of Luc Dochez as independent board member is effective immediately subject to final approval by the next general assembly.
Financial terms:
Latest news:
